3SBio (HK:1530) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
3SBio’s subsidiary, Shenyang Sunshine, has entered into a strategic agreement with Haihe Biopharma to exclusively commercialize Paclitaxel Oral Solution in Mainland China and Hong Kong. This collaboration involves Shenyang Sunshine making initial and milestone payments to RMX Biopharma, which will continue overseeing clinical trials and development. Investors are advised to remain cautious as the product’s successful commercialization is not guaranteed.
For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.